Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia I Toth

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cell Chemical Biology|April 23, 2016
p97 Composition Changes Caused by Allosteric Inhibition Are Suppressed by an On-Target Mechanism that Increases the Enzyme's ATPase ActivityNam-Gu Her, Julia I Toth, Chen-Ting Ma, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2010
Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiencyCatherine Coffinier, Sandy Y Chang, Chika Nobumori, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 2005
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromesJulia I Toth, Shao H Yang, Xin Qiao, et al.
EMBO Reports|June 27, 2009
REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligaseSamiksha Katiyar, Enbo Liu, Christine A Knutzen, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2005
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutationShao H Yang, Martin O Bergo, Julia I Toth, et al.
Molecular Cancer Therapeutics|July 5, 2024
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11Gregory S Parker, Julia I Toth, Sarah Fish, et al.
Molecular Cancer Therapeutics|June 22, 2024
Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11Gregory S Parker, Julia I Toth, Sarah Fish, et al.
ACS Medicinal Chemistry Letters|May 20, 2026
Discovery and Structural Optimization of BRD4-Selective Monovalent Direct DegradersGeoffray Leriche, Farhana Barmare, Julia I Toth, et al.
Plos One|April 3, 2014
Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cellsG Wei Xu, Julia I Toth, Sara R da Silva, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cell Chemical Biology|April 23, 2016
p97 Composition Changes Caused by Allosteric Inhibition Are Suppressed by an On-Target Mechanism that Increases the Enzyme's ATPase ActivityNam-Gu Her, Julia I Toth, Chen-Ting Ma, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2010
Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiencyCatherine Coffinier, Sandy Y Chang, Chika Nobumori, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 2005
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromesJulia I Toth, Shao H Yang, Xin Qiao, et al.
EMBO Reports|June 27, 2009
REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligaseSamiksha Katiyar, Enbo Liu, Christine A Knutzen, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2005
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutationShao H Yang, Martin O Bergo, Julia I Toth, et al.
Molecular Cancer Therapeutics|July 5, 2024
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11Gregory S Parker, Julia I Toth, Sarah Fish, et al.
Molecular Cancer Therapeutics|June 22, 2024
Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11Gregory S Parker, Julia I Toth, Sarah Fish, et al.
ACS Medicinal Chemistry Letters|May 20, 2026
Discovery and Structural Optimization of BRD4-Selective Monovalent Direct DegradersGeoffray Leriche, Farhana Barmare, Julia I Toth, et al.
Plos One|April 3, 2014
Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cellsG Wei Xu, Julia I Toth, Sara R da Silva, et al.
Pageof 2